Early access
Sign in
Taking people in FrancePhase 3

Long-term study of ocrelizumab in French people with progressive multiple sclerosis

Tests ocrelizumab over the long term in adults with progressive multiple sclerosis.

Key facts

Who runs it
Centre Hospitalier Universitaire De Nice
Where
Amiens, Bayonne, Bordeaux, Bron, Caen Cedex 9, Clermont-Ferrand, Lille Cedex, Marseille, Montpellier Cedex 5, Nancy, Nantes Cedex 1, Nice, Nîmes, Rennes, and Strasbourg Cedex 2, FranceSee the 15 sites
Registry title
LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS: CONSONANCE EXTENSION STUDY
Status
Recruiting
Phase
Phase 3
People taking part
89 people, planned
Started
19 Sept 2024
Planned end
21 Sept 2026
Type of study
Interventional
Record updated
30 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 64 years with progressive multiple sclerosis (MS). It looks at the long-term effect and safety of ocrelizumab.

Age
18 to 64 years
Sex
All sexes can join.
Disease stage
Progressive multiple sclerosis

Main reasons for not taking part

  • Healthy volunteers cannot join

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in France

  • CHU Amiens - Groupe Hospitalier SudAmiens, FranceTaking people
  • Centre Hospitalier de la Cote BasqueBayonne, FranceTaking people
  • Centre hospitalier Universitaire de BordeauxBordeaux, FranceTaking people
  • Hospices Civils de LyonBron, FranceTaking people
  • Centre Hospitalier Universitaire De Caen NormandieCaen Cedex 9, FranceTaking people
  • Chu Gabriel MontpiedClermont-Ferrand, FranceTaking people
  • Centre Hospitalier Universitaire De LilleLille Cedex, FranceTaking people
  • Centre Hospitalier Regional De MarseilleMarseille, FranceTaking people
  • Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranceTaking people
  • CHRU de NancyNancy, FranceTaking people
  • CHU de Nantes - Hôpital LaennecNantes Cedex 1, FranceTaking people
  • Centre Hospitalier Universitaire de NiceNice, FranceTaking people
  • Centre Hospitalier Universitaire de NîmesNîmes, FranceTaking people
  • Centre Hospitalier Universitaire de RennesRennes, FranceTaking people
  • Les Hopitaux Universitaires De StrasbourgStrasbourg Cedex 2, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Long-term study of ocrelizumab in French people with progressive multiple sclerosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2024-516433-13-00, who can take part
Record updated
30 September 2026